Commentary [to: "Tuberous sclerosis"] Commentary
Article Sidebar
Published:
May 31, 2011
Main Article Content
Abstract
None
Downloads
Download data is not yet available.
Article Details
How to Cite
1.
Jóźwiak S. Commentary [to: "Tuberous sclerosis"]. OncoReview [Internet]. 2011May31 [cited 2024Nov.23];1(2(2):139-41. Available from: https://journalsmededu.pl/index.php/OncoReview/article/view/246
Issue
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
1. Curatolo P., Bombardieri R., Jozwiak S.: Tuberous sclerosis. Lancet 2008; 372: 657-668.
2. Vogt H.: Zur Diagnostik der Tuberosen Sklerose. Z. Erforsch. Behandl. jugendl. Schwachsinns. 1908; 2: 1-12.
3. Gomez M.R.: Tuberous sclerosis. Raven Press, New York 1988.
4. Jóźwiak S., Domańska-Pakieła D., Kotulska K., Kaczorowska M.: Treatment before seizures: new indications for antiepileptic therapy in children with tuberous sclerosis complex. Epilepsia 2007; 48(8): 1632-5.
5. Jóźwiak S., Kotulska K., Domańska-Pakieła D., Łojszczyk B., Syczewska M., Chmielewski D., Dunin-Wąsowicz D., Kmieć T., Szymkiewicz-Dangel J., Kornacka M., Kawalec W., Kuczyński D., Borkowska J., Tomaszek K., Jurkiewicz E., Respondek-Liberska M.: Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex. Eur. J. Paediatr. Neurol. 2011. Epub ahead of print
6. Bissler J., McCormack F.X., Young L.R., Elwing J.M., Chuck G., Leonard J.M., Schmithorst V.J., Laor T., Brody A.S., Bean J., Salisbury S., Franz D.N.: Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis. NEJM 2008; 358: 140-51.
7. Grajkowska W., Kotulska K., Jurkiewicz E., Matyja E.: Brain lesions in tuberous sclerosis complex. Folia Neuropathol. 2010; 48(3): 139-49.
8. Franz D.N., Leonard J., Tudor C., Chuck G., Care M., Sethuraman G., Dinopoulos A., Thomas G., Crone K.R.: Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann. Neurol. 2006; 59(3): 490-8.
9. Krueger D.A., Care M.M., Holland K., Agricola K., Tudor C., Mangeshkar P., Wilson K.A., Byars A., Sahmoud T., Franz D.N.: Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. NEJM 2010; 363(19): 1801-11.
10. Hofbauer G.F., Marcollo-Pini A., Corsenca A., Kistler A.D., French L.E., Wüthrich R.P., Serra A.L.: The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis. Br. J. Dermatol. 2008; 159(2): 473-5.
2. Vogt H.: Zur Diagnostik der Tuberosen Sklerose. Z. Erforsch. Behandl. jugendl. Schwachsinns. 1908; 2: 1-12.
3. Gomez M.R.: Tuberous sclerosis. Raven Press, New York 1988.
4. Jóźwiak S., Domańska-Pakieła D., Kotulska K., Kaczorowska M.: Treatment before seizures: new indications for antiepileptic therapy in children with tuberous sclerosis complex. Epilepsia 2007; 48(8): 1632-5.
5. Jóźwiak S., Kotulska K., Domańska-Pakieła D., Łojszczyk B., Syczewska M., Chmielewski D., Dunin-Wąsowicz D., Kmieć T., Szymkiewicz-Dangel J., Kornacka M., Kawalec W., Kuczyński D., Borkowska J., Tomaszek K., Jurkiewicz E., Respondek-Liberska M.: Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex. Eur. J. Paediatr. Neurol. 2011. Epub ahead of print
6. Bissler J., McCormack F.X., Young L.R., Elwing J.M., Chuck G., Leonard J.M., Schmithorst V.J., Laor T., Brody A.S., Bean J., Salisbury S., Franz D.N.: Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis. NEJM 2008; 358: 140-51.
7. Grajkowska W., Kotulska K., Jurkiewicz E., Matyja E.: Brain lesions in tuberous sclerosis complex. Folia Neuropathol. 2010; 48(3): 139-49.
8. Franz D.N., Leonard J., Tudor C., Chuck G., Care M., Sethuraman G., Dinopoulos A., Thomas G., Crone K.R.: Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann. Neurol. 2006; 59(3): 490-8.
9. Krueger D.A., Care M.M., Holland K., Agricola K., Tudor C., Mangeshkar P., Wilson K.A., Byars A., Sahmoud T., Franz D.N.: Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. NEJM 2010; 363(19): 1801-11.
10. Hofbauer G.F., Marcollo-Pini A., Corsenca A., Kistler A.D., French L.E., Wüthrich R.P., Serra A.L.: The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis. Br. J. Dermatol. 2008; 159(2): 473-5.